C. Rubino1; W. Z. Bradford2; A. Forrest1; S. Porter2; L. M. Blatt2; S. Seiwert2; S. Zeuzem3
1. ICPD/Ordway Research Institute, Inc., Albany, NY, USA.
2. Intermune, Inc, Brisbane, CA, USA.
3. J.W. Goethe Universität, Frankfurt, Germany.
ITMN-191 is a highly potent, slowly dissociating NS3/4A protease inhibitor designed to achieve high liver concentrations with only modest plasma exposure. This study examines PK-PD relationships for ITMN-191 in CHC patients.
Methods: Four cohorts of 10 naïve patients were randomized (8:2) to receive oral ITMN-191 (100 mg q12h, 100 mg q8h, 200 mg q12h, or 200 mg q8h) or placebo for 14 days. PK parameters and PK-PD relationships were assessed using non-compartmental methods and non-linear models, respectively.
Results: ITMN-191 showed potent antiviral activity with relatively low plasma concentrations. At 200 mg q8h, the mean AUC0-24, Cmax, and Cmin values were 500 ng×h/mL, 91 ng/mL and 2.78 ng/mL, respectively, and the mean max. decline in HCV RNA was 3.9 log10.The dose-exposure relationship was not uniformly proportional.Predicted Cmin values for 2, 3, and 4 log10 HCV RNA declines were 0.07, 0.19, and 2.7 ng/mL, respectively. In an inhibitory Emax model, the strongest relationship was between Day 1 Cmin and max change in HCV RNA (figure); fitted Eo, Emax and EC50 values were -0.33 log10, 3.6 log10 and 0.08 ng/mL, respectively. Conclusion: ITMN-191 achieves significant antiviral effects with substantially lower plasma exposures than reported for other NS3 inhibitors. This is consistent with the high liver:plasma concentration ratios seen in animals and likely contributes to the favorable safety and antiviral activity in patients. These data, plus in vitro evidence of synergy with peginterferon, provide a strong rationale for the ongoing triple combination study to further evaluate the PK-PD and antiviral effect of an ITMN-191.
Observed Data and Fitted PK-PD relationship for ITMN-191
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM